Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06073470

Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With ADHD

To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Methylphenidate Metabolomics

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

National Taiwan University Hospital

Taipei, 110, Taiwan

Location status: Recruiting

Location contact

Chi-Yung Shang, MDPHD

CONTACT

[email protected]

02-23123456 ext. 266965

About this study

Although the efficacy of methylphenidate in reducing the core symptoms of attentiondeficit/ hyperactivity disorder (ADHD) is well documented in clinical trials, no definite biomarker has been identified to differentiate responders from non-responders to methylphenidate treatment for children with ADHD. In addition, the neural and metabolic mechanisms underlying the therapeutic effects of methylphenidate remain to be elucidated. In this 4-year prospective project, the investigators will explore the effects of 12-week treatment with methylphenidate on the electrophysiology and metabolomics of children with ADHD to identify the biomarkers for predicting the clinical response to methylphenidate. In addition, the investigators will explore the metabolic mechanisms through which methylphenidate treatment may modulate the abnormality in the electrophysiology of children with ADHD.

Specific Aims:

  • To examine the differences in electrophysiology and metabolomics between children with ADHD and neurotypical controls.
  • To examine the differences in the change of electrophysiology and metabolomics after 12-week treatment with methylphenidate between responders and non-responders in children with ADHD.
  • To explore the relationship of treatment-related changes in electrophysiology and those in metabolomics for identification of the underlying metabolic mechanisms for the electrophysiological effects of methylphenidate in children with ADHD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

  • Patients with ADHD
  • Inclusion Criteria
  • Patients, aged 6 to 18 years, meet the DSM-5 diagnostic criteria for ADHD.
  • At baseline, patients have a Clinical Global Impressions-ADHD-Severity (CGI-ADHD-S) score greater than 4.
  • Patients have a Full IQ (FIQ) score greater than 80.
  • Exclusion Criteria
  • Patients have a major psychiatric disorder, such as autism spectrum disorder, schizophrenia, affective disorders, or substance use disorders.
  • Patients have a major disorder of central nervous system, such as epilepsy.
  • Patients have a major systemic disease, such as diabetes mellitus or cardiovascular diseases.
  • Patients have ever received any medication to treat the clinical symptoms of ADHD.
  • Neurotypical participants:
  • Inclusion Criteria
  • aged 6 to 18 years
  • All of the neurotypical participants have no psychiatric disorder in lifetime according to the diagnostic criteria of DSM-5.
  • Exclusion Criteria
  • participants have any disorder of central nervous system or major systemic disease
  • participants have ever taken any psychotropic drug, or who have FIQ scores less than 80, will be excluded from the present study.

Treatment and study plan

Methylphenidate

Drug

The patients with ADHD will receive 12-week treatment with methylphenidate.

Primary outcomes

  1. Diagnostic interview

    Time frame: 1 hour

    We will interview all the participants and their parents to examine whether the participants have any psychiatric disorder by employing the Kiddie Epidemiologic version of the Schedule for Affective Disorders and Schizophrenia (K-SADS-E).

  2. ADHD symptoms

    Time frame: 15 minutes

    Subjects will be interviewed by ADHD rating scale , which consists of 18 items to measure the symptomatology of ADHD . Each question in this questionnaire is scaled from 0 to 3. The higher the total score, the more severe the symptoms.

Secondary outcomes

  1. Questionnaire

    Time frame: 5minutes

    Cases and parents assisted in filling out the Achenbach child behavior check list (CBCL).Each question in this questionnaire is scaled from 1 to 3. The higher the total score, the more severe the emotional and behavioral distress.

  2. Questionnaire

    Time frame: 5minutes

    Cases and parents assisted in filling out the Swanson, Nolan, and Pelham Rating Scale Fourth Edition (SNAP-IV).Each question in this questionnaire is scaled from 0 to 3. The higher the total score, the more severe the symptoms.

  3. Questionnaire

    Time frame: 5minutes

    Cases and parents assisted in filling out the Family APGAR questionnaire.Each question in this questionnaire is scaled from 0 to 2. The higher the total score, the better the family function.

  4. Questionnaire

    Time frame: 5minutes

    Cases and parents assisted in filling out the Social Adjustment Inventory for Children and Adolescents questionnaire (SAICA).The scale for each question in this questionnaire ranges from 1 to 4. The higher the total score, the worse the social adaptation status.

  5. Questionnaire

    Time frame: 5minutes

    Cases and parents assisted in filling out the Behavior Rating Inventory of Executive Function questionnaire(BRIEF).Each question in this questionnaire is scaled from 1 to 3. The higher the total score, the lower the executive function status.

  6. Neurobiological assessments

    Time frame: 10minutes

    Resting state EEG will be recorded in NTUH ERP lab.The EEG will be processed for functional connectivity indices between regions are calculated using the magnitude squared coherence (Coh) in the delta(delta)/theta(theta)/alpha(alpha)/beta(beta) frequency bands and the nonlinear index (L) of generalized synchronization.

  7. Neurobiological assessments

    Time frame: 10minutes

    Resting state EEG will be recorded in NTUH ERP lab. Phase transfer entropy (PTE) will be used to construct the effective connectivity. The topological properties of networks and flow gain are measured separately in four bands (delta, theta, alpha, and beta).

  8. Neurobiological assessments

    Time frame: 10minutes

    Resting state EEG will be recorded in NTUH ERP lab. We will perform Fast Fourier Transform using the pwelch algorithm, with a 128 sample triangular window, to obtain time-frequency domain measures. Mean spectral estimates in various power bands are computed. As a measure of intraindividual variability in neural activity, the standard deviation of the power in each 2-second trial is calculated for each band for each participant.

  9. Neurobiological assessments

    Time frame: 30minutes

    auditory MMN/P3a (task-free ERP) will be recorded in NTUH ERP .

  10. Neurobiological assessments

    Time frame: 20minutes

    dichotic continuous performance task(DCPT, task-related ERP modified from Conner's CATA) will be recorded in NTUH ERP lab.

  11. liquid chromatography-mass spectrometry and gas chromatography-mass spectrometry

    Time frame: 5 minutes

    Whole blood samples will be collected after 8 hours of fasting at baseline and week 12 for neurotypical controls and for patients with ADHD. The investigators will employ both liquid chromatography coupled to mass spectrometry (LC/MS) and gas chromatography coupled to mass spectrometry (GC/MS) to conduct the experiments of metabolomic profiling of the serum at the Metabolomics Core Laboratory, National Taiwan University.

  12. Neuropsychological testing

    Time frame: 1.5 hours

    Subjects will be assessed by the WISC-V(Wechsler Intelligence Scale for Children),WISC-V scores between 90 and 109 represent moderate general intelligence, and higher scores represent relatively better cognitive function.

Study contacts

Contact information is provided by the study sponsor or research team.

Chi-Yung Shang, MD, PhD

CONTACT

[email protected]

+886-2-23123456 ext. 66965

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Official study title

Exploration of the Metabolic Mechanisms of the Electrophysiological Biomarkers for Response to Methylphenidate Treatment in Children With Attention-Deficit/Hyperactivity Disorder

Important dates

Study start
2024
Primary completion
2027
Study completion
2027
First posted
Oct 10, 2023
Registry last updated
Mar 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.